Genmab (GMAB) Price & Analysis

Compare

678 Followers

GMAB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$17.24 - $28.75

Previous CloseN/A

Volume229.76K

Average Volume (3M)1.41M

Market Cap

$17.41B

Enterprise Value$9.96B

Total Cash (Recent Filing)$18.37B

Total Debt (Recent Filing)$937.88M

Price to Earnings (P/E)13.8

Beta0.51

Next Earnings

Nov 06, 2025

EPS Estimate

0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.54

Shares Outstanding641,588,130

10 Day Avg. Volume1,545,796

30 Day Avg. Volume1,410,305

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.57

Enterprise Value/Revenue0.44

Enterprise Value/Gross Profit0.46

Enterprise Value/Ebitda1.30

Forecast

1Y Price Target

$32.75

Price Target Upside17.72% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial PerformanceGenmab recorded a diluted net income of $5.42 per share, which exceeded the previously forecasted $4.13 per share.

Pipeline DevelopmentThe potential FDA approval for the combination of epcoritamab + rituximab for treating relapsed or refractory follicular lymphoma is highlighted as a significant upcoming catalyst.

Revenue GrowthGenmab generated $925M in revenue for the quarter, with DARZALEX royalties coming in at $638M, surpassing the estimate of $606M.

Bears Say

Competitive ChallengesData to date in NSCLC for acasunlimab has been lackluster in a highly competitive space.

Patent Expiration RiskThe outlook remains guarded given uncertainty as to whether Genmab can overcome the Darzalex patent cliff by 2030.

Genmab News

Genmab price target raised to DKK 1,650 from DKK 1,500 at JPMorgan

JPMorgan raised the firm’s price target on Genmab (GMAB) to DKK 1,650 from DKK 1,500 and keeps a...

4d ago

GMAB

Genmab price target raised to DKK 1,900 from DKK 1,750 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Genmab (GMAB) to DKK 1,900 from DKK 1,750 and keeps...

18d ago

GMAB

Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan

Genmab (GMAB) announced that the FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan, an investigational folate receptor...

21d ago

GMAB

Genmab A/S Updates Articles of Association to Boost Financial Flexibility

The latest update is out from Genmab ( ($GMAB) ). On September 10, 2025, Genmab A/S announced updates...

5d ago

GMAB

Genmab Announces Capital Increase Following Employee Warrant Exercise

Genmab ( ($GMAB) ) just unveiled an announcement. On September 9, 2025, Genmab A/S announced a capital increase...

6d ago

GMAB

Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on GMAB stock, giving a Buy rating today....

1M ago

GMAB

Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating

Genmab, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C....

1M ago

GMAB

Genmab price target raised to $36 from $35 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy...

1M ago

GMAB

Genmab’s Tisotumab Vedotin Study: A Promising Update for Solid Tumor Treatment

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. The study titled Open Label Phase 2...

1M ago

GMAB

Genmab’s Cervical Cancer Study: A Potential Game-Changer?

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A...

1M ago

GMAB

Genmab Updates Articles to Boost Financial Flexibility

Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its...

1M ago

GMAB

Genmab’s Earnings Call Highlights Strong Growth and Pipeline Success

Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

GMAB

Genmab Announces Capital Increase Following Employee Warrant Exercise

Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announced a capital increase...

1M ago

GMAB

Genmab’s Tisotumab Vedotin Study: A Potential Game-Changer in Cancer Treatment

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Genmab, in collaboration with Seagen and Merck...

1M ago

GMAB

GMAB FAQ

What was Genmab A/S’s price range in the past 12 months?

Genmab A/S lowest stock price was $17.23 and its highest was $28.75 in the past 12 months.

What is Genmab A/S’s market cap?

Genmab A/S’s market cap is $17.41B.

When is Genmab A/S’s upcoming earnings report date?

Genmab A/S’s upcoming earnings report date is Nov 06, 2025 which is in 51 days.

How were Genmab A/S’s earnings last quarter?

Genmab A/S released its earnings results on Aug 07, 2025. The company reported $0.542 earnings per share for the quarter, beating the consensus estimate of $0.399 by $0.143.

Is Genmab A/S overvalued?

According to Wall Street analysts Genmab A/S’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genmab A/S pay dividends?

Genmab A/S does not currently pay dividends.

What is Genmab A/S’s EPS estimate?

Genmab A/S’s EPS estimate is 0.45.

How many shares outstanding does Genmab A/S have?

Genmab A/S has 641,588,130 shares outstanding.

What happened to Genmab A/S’s price movement after its last earnings report?

Genmab A/S reported an EPS of $0.542 in its last earnings report, beating expectations of $0.399. Following the earnings report the stock price went up 5.486%.

Which hedge fund is a major shareholder of Genmab A/S?

Currently, no hedge funds are holding shares in GMAB

Genmab Stock Smart Score

Outperform

Fundamentals

Return on Equity

26.08%

Trailing 12-Months

Asset Growth

16.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genmab A/S

Genmab (GMAB) is a leading international biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on creating innovative treatments that harness the body's immune system to combat malignancies. The company is known for its proprietary technologies, such as the DuoBody platform, which enables the development of bispecific antibodies, and has a robust pipeline of product candidates, including its flagship drug, Darzalex (daratumumab), used in multiple myeloma treatment.

Genmab (GMAB) Earnings & Revenues

Historic Earnings Reports

GMAB Company Deck

GMAB Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.View all GMAB earnings summaries

GMAB Stock 12 Month Forecast

Average Price Target

$32.75

▲(17.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","32":"$32","47":"$47","24.5":"$24.5","39.5":"$39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,24.5,32,39.5,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.89,27.436923076923076,28.983846153846155,30.53076923076923,32.07769230769231,33.62461538461538,35.17153846153846,36.71846153846154,38.26538461538462,39.81230769230769,41.35923076923077,42.90615384615384,44.45307692307692,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.89,26.41769230769231,26.945384615384615,27.473076923076924,28.00076923076923,28.52846153846154,29.056153846153848,29.583846153846153,30.111538461538462,30.63923076923077,31.166923076923077,31.694615384615386,32.222307692307695,{"y":32.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.89,25.744615384615386,25.59923076923077,25.453846153846154,25.30846153846154,25.163076923076922,25.017692307692307,24.872307692307693,24.72692307692308,24.58153846153846,24.436153846153847,24.290769230769232,24.145384615384614,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.56,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.67,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >